Tuesday, March 23, 2027 - 8:00 AM
to Thursday, March 25, 2027 - 5:00 PM
8:00 AM - 5:00 PM See all dates and Times
The immune tolerance field is entering a defining moment. As developers seek to move beyond chronic immunosuppression and toward therapies capable of delivering durable disease modification, antigen-specific immune tolerance approaches are rapidly advancing from preclinical promise into clinical reality. The 10th Antigen-Specific Immune Tolerance Summit will unite the scientific, clinical, and commercial leaders shaping the future of autoimmune disease treatment. This meeting will bring together experts from biopharma, academia, investor organizations, and immunology-focused pharma teams to accelerate the development of transformative tolerance-inducing therapies.
Designed specifically for senior decision-makers, scientific leaders, and immunology innovators, the summit will explore the key challenges and opportunities defining the next phase of development. Discussions will focus on establishing meaningful biomarkers of tolerance, evaluating durability of response, improving preclinical-to-clinical translation, refining antigen selection strategies, and advancing delivery technologies. Attendees will gain exclusive insights from organizations actively advancing the field, including Diamyd Medical, COUR Pharmaceuticals, Parvus Therapeutics, Bonsai Biotherapeutics, EVOQ Therapeutics, Pfizer, Eli Lilly, and the Immune Tolerance Network.
Key sessions will showcase emerging clinical and translational data, lessons learned from ongoing trials, strategies for monitoring therapeutic efficacy, the role of infectious disease in autoimmunity, regulatory considerations, and partnership and investment priorities critical to advancing next-generation immune tolerance therapies. From Type 1 diabetes and celiac disease to multiple sclerosis, rheumatoid arthritis, and other autoimmune disorders, the meeting provides a unique opportunity to benchmark progress across indications and therapeutic modalities.
As part of World Immune Tolerance Week, attendees will also gain access to the 9th Treg-Directed Therapies Summit and 2nd Immune Resetting: B-Cell Mediated & Beyond Summit, creating unparalleled networking opportunities with leaders advancing precision immunology, immune modulation, and autoimmune disease innovation.
Join the global immune tolerance community in Boston to connect with CEOs, CSOs, CBOs, VPs, Directors, translational scientists, and immunology experts dedicated to delivering the next generation of therapies capable of resetting the immune system and transforming outcomes for patients with autoimmune disease.
Event Links
Website: https://go.evvnt.com/3898346-0
Tickets: https://go.evvnt.com/3898346-2
Brochure: https://go.evvnt.com/3898346-3
